Clinical therapy research, inflammatory diseases (ClinTRID) is a new unit at Karolinska Institutet with offices at the Karolinska University Hospital. The unit consists of a professor and chief, researchers with clinical and preclinical backgrounds, graduate students and a unit administrator. We have special expertise in registry studies, clinical trials, medicine, nutrition and molecular biology, with experience in the conducting productive collaborations, and an ability to coordinate and maintain long-term projects. In addition, we ensure that we remain at the forefront through continuous education.
Chronic inflammatory diseases, which can also be called systemic diseases or autoimmune diseases, can cause major damage to body tissues, with effects on individual organ function and sometimes even the whole body. What causes a chronic inflammation is not entirely clear, although there are indications that some genetic backgrounds and/or environmental factors may be a trigger. But it is clear that people with chronic inflammatory diseases tend to undergo great suffering because of symptoms caused by inflammation but also because of constant medication and side effects from medications. Although there has recently been significant progress in the therapy field, even today there are few patients for whom treatment is 100 per cent effective.
Goals and future
We are an innovative unit that intends to achieve our goals through clear focus and targeted partnerships. In the current situation, we have close collaborations with the rheumatology clinic at Karolinska University Hospital and the Rheumatology Unit at Karolinska Institutet, but also with medical specialists in gastroenterology, dermatology, and neurology, and with the Theme Center Inflammation. In time, we look forward to also working with many different specialists in the context of the New Karolinska Hospital (NKS) in Solna. We aim to answer questions in treatment research through professional multidisciplinary collaborations. Our tools are prospective clinical trials and observational, often register-based studies, modern imaging with ultrasound, and access to new laboratory techniques through collaborations with research laboratories and research-oriented companies. We analyze effectiveness and safety of various treatments and treatment strategies, as well as gender aspects of treatments and the increasingly important field of health economics. The long-term objective of our research is to find answers that may help to treat inflammatory diseases in a more optimized and personalized manner, and in due course, to prevent diseases and to approach the possibility of curing some patients.
|NORD-STAR||Nordic randomized clinical trial in early RA. Initial 4-way randomization (conventional vs 3 biologics); re-randomization for patients in remission to immediate vs delayed step-down therapy (800 patients).||Monica Rydén Aulin|
|CO-STAR||Nordic randomized trial in early RA for patients in LDA, immediate vs delayed step-down therapy (400 patients)||Monica Rydén Aulin|
|NORD-STAR ultrasound||Follow-up of disease activity using musculoskeletal ultrasound in patients with early rheumatoid arthritis||Yogan Kisten|
|MUSCARA: ultrasound support in choice of therapy||Prospective Swedish collaborative project (120)||Hamed Rezaei|
|SWEFOT long-term follow-up||5-year clinical, radiological, and health-economic evaluation||Ronald van Vollenhoven|
|SWEFOT Biomarkers||Biomarkers in early RA, in collaboration with Crescendo (487).||Karen Hambardzumyan|
|SWEFOT omics||Biomarkers in early RA, in collaboration with Per-Johan Jakobsson||Karen Hambardzumyan|
|SWEFOT Adipokines||Adipokines in early RA, extension study||Adrian Levitsky|
|FIN/NEORACO POPERA||Collaboration with Vappu Rantalaiho and colleagues in Finland.||Ronlad van Vollenhoven|
|Diet and treatment results in RA and SLE||800 RA cases from EIRA & 114 SLE cases from SLEVIC||Cecilia Lourdudoss|
|Diet and pain in RA||1.296 RA cases from EIRA||Cecilia Lourdudoss|
|Dietary changes after RA diagnosis||130 RA cases from SMC||Cecilia Lourdudoss|
|Diet and plaque in SLE||114 SLE cases from SLEVIC||Cecilia Lourdudoss|
|ARTIS CZP||Certolizumab in RA, ARTIS registry study(400)||Katerina Chatzidionysiou|
|SLE pattern study - Collaboration with Hopkins Lupus Centre||A retrospective descriptive analysis of the Hopkins Lupus cohort to discern and describe SLE disease activity patterns over time. (2000 patients)||Noémi Györi|
|Kaltenborn mobilization and ultrasound study||Utilization of Kaltenborn manual mobilization for pain and Doppler reduction in patients with RA.||Adrian Levitsky|
|Definition of Remission in SLE (DORIS).||International consensus finding followed by analyses.||Sharzad Emamikia|
|Glucocorticoid side effects.||Post-hoc analysis of BLISS dataset.||Sharzad Emamikia|
|HITHARD/Guepard meta-analysis||Systematic literature review and meta-analysis of randomized trials on induction-maintenance strategies for RA.||Sharzad Emamikia|